HRP20220502T1 - Kombinacije koje sadrže derivate 5-fenoksi-3h-pirimidin-4-ona i njihova uporaba za profilaksu ili liječenje infekcije hiv-om - Google Patents

Kombinacije koje sadrže derivate 5-fenoksi-3h-pirimidin-4-ona i njihova uporaba za profilaksu ili liječenje infekcije hiv-om Download PDF

Info

Publication number
HRP20220502T1
HRP20220502T1 HRP20220502TT HRP20220502T HRP20220502T1 HR P20220502 T1 HRP20220502 T1 HR P20220502T1 HR P20220502T T HRP20220502T T HR P20220502TT HR P20220502 T HRP20220502 T HR P20220502T HR P20220502 T1 HRP20220502 T1 HR P20220502T1
Authority
HR
Croatia
Prior art keywords
alkyl
haloalkyl
independently
substituents
ariq
Prior art date
Application number
HRP20220502TT
Other languages
English (en)
Inventor
Kenneth L. Arrington
Christopher Burgey
Robert Gilfillan
Yongxin Han
Mehul Patel
Chun Sing Li
Yaozong LI
Yunfu Luo
Jiayi Xu
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of HRP20220502T1 publication Critical patent/HRP20220502T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Claims (15)

1. Kombinacija koja sadrži (i) spoj formule (Ia): [image] ili njegovu farmaceutski prihvatljivu sol i (ii) jedno ili više sredstava protiv HIV-a izabranih od antivirusnih sredstava protiv HIV-a, imunomodulatora i anti-infektivnih sredstava, gdje: M je CH2, CH2CH2, CH2CH2CH2, CH(CH3), C(CH3)2 ili C(O)N(RA); Z je izabran iz grupe koja se sastoji od: piridazina, piridazinona, pirimidina, pirimidinona, pirazina, pirazinona, triazina i triazinona, svaki izborno supstituiran sa jednim ili više supstituenata do maksimalnog broja dozvoljenog valentnošću izabranog od R4 i R5; svaki K1 i K2 su neovisno F, Br, Cl, OCHF2, CF3 ili CN; R2 je izabran iz grupe koja se sastoji od: (1) H, (2) C1-6 alkila, (3) C1-6 haloalkila, (4) C1-6 alkila supstituiranog sa od 1 do 3 supstituenta od kojih je svaki neovisno OH, O-C1-6 alkil, O-C1-6 haloalkil, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB ili N(RA)C(O)C(O)N(RA)RB, (5) O-C1-6 alkila u kojem je alkil izborno supstituiran sa 1 do 3 supstituenta neovisno izabrana od OH, O-C1-6 alkila, O-C1-6 haloalkila, CN, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, ili S(O)2N(RA)RB, (6) O-C1-6 haloalkila, (7) halogena, (8) CN, (9) NO2, (10) N(RA)RB, (11) C(O)N(RA)RB, (12) C(O)RA, (13) C(O)-C1-6 haloalkila, (14) C(O)ORA, (15) OC(O)RA, (16) OC(O)N(RA)RB, (17) SRA, (18) S(O)RA, (19) S(O)2RA, (20) S(O)2N(RA)RB, (21) N(RA)S(O)2RB, (22) N(RA)S(O)2N(RA)RB, (23) N(RA)C(O)RB, (24) N(RA)C(O)N(RA)RB, (25) N(RA)C(O)-C(O)N(RA)RB, (26) N(RA)CO2RB, (27) N(RC)RD, (28) C(O)N(RC)RD, (29) OC(O)N(RC)RD, (30) S(O)2N(RC)RD, (31) N(RA)S(O)2N(RC)RD, (32) N(RA)C(O)N(RC)RD, (33) N(RA)C(O)-C(O)N(RC)RD, (34) CycA, (35) -O-CycA, (36) ArilA, ili (37) HetA; R3 je H, C1-6 alkil, halogen, CN, C1-6 fluoroalkil, OH, O-C1-6 alkil ili O-C1-6 haloalkil; R4 i R5 su svaki neovisno izabrani od: (1) H, (2) C1-6 alkila, C2-6 alkenila ili C2-6 alkinila, svaki izborno supstituiran sa jednim ili više supstituenata do maksimalnog broja dozvoljenog valentnošću izabranog od OH, O-C1-6 alkila, O-C1-6 haloalkila, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C(O)C(O)N(RA)RB, CycB, ArilB i HetB, (3) C1-6 haloalkila izborno dodatno supstituiranog sa jednim ili više supstituenata do maksimalnog broja dozvoljenog valentnošću izabranog od OH, O-C1-6 alkila, O-C1-6 haloalkila, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C(O)C(O)N(RA)RB, CycB, ArilB i HetB (4) O-C1-6 alkila u kojem je dio alkila izborno supstituiran sa jednim ili više supstituenata do maksimalnog broja dozvoljenog valentnošću izabranog od OH, O-C1-6 alkila, O-C1-6 haloalkila, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C(O)C(O)N(RA)RB, CycB, ArilB i HetB, (5) O-C1-6 haloalkila, izborno dodatno supstituiranog sa jednim ili više supstituenata do maksimalnog broja dozvoljenog valentnošću izabranog od OH, O-C1-6 alkila, O-C1-6 haloalkila, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, N(RA)C(O)C(O)N(RA)RB, CycB, ArilB i HetB, (6) halogena, (7) CN, (8) NO2, (9) N(RA)RB, (10) C(O)N(RA)RB, (11) C(O)RA, (12) C(O)-C1-6 haloalkila, (13) C(O)ORA, (14) OC(O)RA, (15) OC(O)N(RA)RB, (16) SRA, (17) S(O)RA, (18) S(O)2RA, (19) S(O)2N(RA)RB, (20) N(RA)S(O)2RB, (21) N(RA)S(O)2N(RA)RB, (22) N(RA)C(O)RB, (23) N(RA)C(O)N(RA)RB, (24) N(RA)C(O)-C(O)N(RA)RB, (25) N(RA)CO2RB, (26) N(RC)RD, (27) C(O)N(RC)RD, (28) OC(O)N(RC)RD, (29) S(O)2N(RC)RD, (30) N(RA)S(O)2N(RC)RD, (31) N(RA)C(O)N(RC)RD, (32) N(RA)C(O)-C(O)N(RC)RD, (33) OH, (34) CycB, (35) ArilB, (36) HetB, (37) -J-CycB, (38) -J-ArilB, i (39) -J-HetB, ili R4 i R5 na susjednim atomima mogu biti spojeni zajedno sa atomima za koje su vezani tako da formiraju fuzionirani CycC, ArilC ili HetC; CycA, CycB i CycC su neovisno karbociklil koji je C3-8 cikloalkil, C5-8 cikloalkenil ili C7-12 bicikličan, zasićeni ili nezasićeni, nearomatičan sustav prstena u kojem je jedan prsten fuzioniran za ili premošćen sa drugim prstenom; pri čemu je karbociklil izborno supstituiran sa ukupno od 1 do 6 supstituenata, pri čemu: (i) od nula do 6 supstituenata su svaki neovisno: (1) halogen, (2) CN, (3) C1-6 alkil, (4) OH, (5) O-C1-6 alkil, (6) C1-6 haloalkil, (7) O-C1-6 haloalkil, (8) C1-6 alkenil, ili (9) C1-6 alkenil supstituiran sa CN, i (ii) od nula do 2 supstituenta su svaki neovisno: (1) CycQ, (2) AriQ, (3) HetQ, (4) HetR, (5) J-CycQ, (6) J-AriQ, (7) J-HetQ, (8) J-HetR, (9) C1-6 alkil supstituiran sa CycQ, AriQ, HetQ, HetR, J-CycQ, J-AriQ, J-HetQ, ili J-HetR, (10) C2-6 alkenil supstituiran sa CycQ, AriQ, HetQ, HetR, J-CycQ, J-AriQ, J-HetQ, ili J-HetR, ili (11) C2-6 alkinil supstituiran sa CycQ, AriQ, HetQ, HetR, J-CycQ, J-AriQ, J-HetQ, ili J-HetR; ArilA, ArilB i ArilC su neovisno aril koji je izborno supstituiran sa ukupno od 1 do 8 supstituenata, pri čemu: (i) od nula do 8 supstituenata su svaki neovisno: (1) C1-6 alkil, (2) C1-6 haloalkil, koji je izborno supstituiran sa 1 do 3 dodatna supstituenta od kojih je svaki neovisno izabran od OH, O-C1-6 alkila, O-C1-6 haloalkila, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, ili N(RA)C(O)C(O)N(RA)RB, (3) C1-6 alkila supstituiranog sa od 1 do 3 supstituenta od kojih je svaki neovisno izabran od OH, O-C1-6 alkila, O-C1-6 haloalkila, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, ili N(RA)C(O)C(O)N(RA)RB, (4) C2-6 alkenil, (5) C2-6 alkenil supstituiran sa od 1 do 3 supstituenta od kojih je svaki neovisno OH, O-C1-6 alkil, O-C1-6 haloalkil, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, ili N(RA)C(O)C(O)N(RA)RB, (6) C2-6 alkinil, (7) C2-6 alkinil supstituiran sa od 1 do 3 supstituenta od kojih je svaki neovisno OH, O-C1-6 alkil, O-C1-6 haloalkil, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, ili N(RA)C(O)C(O)N(RA)RB, (8) O-C1-6 alkil, (9) O-C1-6 haloalkil, (10) OH, (11) halogen, (12) CN, (13) NO2, (14) N(RA)RB, (15) C(O)N(RA)RB, (16) C(O)RA, (17) C(O)-C1-6 haloalkil, (18) C(O)ORA, (19) OC(O)N(RA)RB, (20) SRA, (21) S(O)RA, (22) S(O)2RA, (23) S(O)2N(RA)RB, (24) N(RA)S(O)2RB, (25) N(RA)S(O)2N(RA)RB, (26) N(RA)C(O)RB, (27) N(RA)C(O)N(RA)RB, (28) N(RA)C(O)-C(O)N(RA)RB, ili (29) N(RA)CO2RB, i (ii) od nula do 2 supstituenta su svaki neovisno: (1) CycQ, (2) AriQ, (3) HetQ, (4) HetR, (5) J-CycQ, (6) J-AriQ, (7) J-HetQ, (8) J-HetR, (9) C1-6 alkil supstituiran sa CycQ, AriQ, HetQ, HetR, J-CycQ, J-AriQ, J-HetQ, ili J-HetR, (10) C2-6 alkenil supstituiran sa CycQ, AriQ, HetQ, HetR, J-CycQ, J-AriQ, J-HetQ, ili J-HetR, ili (11) C2-6 alkinil supstituiran sa CycQ, AriQ, HetQ, HetR, J-CycQ, J-AriQ, J-HetQ, ili J-HetR; HetA, HetB i HetC su neovisno heterociklil ili heteroaril koji je izborno supstituiran sa ukupno od 1 do 8 supstituenata, gdje: (i) od nula do 8 supstituenata su svaki neovisno: (1) C1-6 alkil, (2) C1-6 haloalkil, koji je izborno supstituiran sa 1 do 3 dodatna supstituenta od kojih je svaki neovisno izabran od OH, O-C1-6 alkila, O-C1-6 haloalkila, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, ili N(RA)C(O)C(O)N(RA)RB, (3) C1-6 alkil supstituiran sa od 1 do 3 supstituenta od kojih je svaki neovisno izabran od OH, O-C1-6 alkila, O-C1-6 haloalkila, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, ili N(RA)C(O)C(O)N(RA)RB, (4) C2-6 alkenil, (5) C2-6 alkenil supstituiran sa od 1 do 3 supstituenta od kojih je svaki neovisno OH, O-C1-6 alkil, O-C1-6 haloalkil, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, ili N(RA)C(O)C(O)N(RA)RB, (6) C2-6 alkinil, (7) C2-6 alkinil supstituiran sa od 1 do 3 supstituenta od kojih je svaki neovisno OH, O-C1-6 alkil, O-C1-6 haloalkil, CN, NO2, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, S(O)2RA, S(O)2N(RA)RB, N(RA)C(O)RB, N(RA)CO2RB, N(RA)S(O)2RB, N(RA)S(O)2N(RA)RB, OC(O)N(RA)RB, N(RA)C(O)N(RA)RB, ili N(RA)C(O)C(O)N(RA)RB, (8) O-C1-6 alkil, (9) O-C1-6 haloalkil, (10) OH, (11) okso, (12) halogen, (13) CN, (14) NO2, (15) N(RA)RB, (16) C(O)N(RA)RB, (17) C(O)RA, (18) C(O)-C1-6 haloalkil, (19) C(O)ORA, (20) OC(O)N(RA)RB, (21) SRA, (22) S(O)RA, (23) S(O)2RA, (24) S(O)2N(RA)RB, (25) N(RA)S(O)2RB, (26) N(RA)S(O)2N(RA)RB, (27) N(RA)C(O)RB, (28) N(RA)C(O)N(RA)RB, (29) N(RA)C(O)-C(O)N(RA)RB, ili (30) N(RA)CO2Rb, i (ii) od nula do 2 supstituenta su svaki neovisno: (1) CycQ, (2) AriQ, (3) HetQ, (4) HetR, (5) J-CycQ, (6) J-AriQ, (7) J-HetQ, (8) J-HetR, (9) C1-6 alkil supstituiran sa CycQ, AriQ, HetQ, HetR, J-CycQ, J-AriQ, J-HetQ, ili J-HetR, (10) C2-6 alkenil supstituiran sa CycQ, AriQ, HetQ, HetR, J-CycQ, J-AriQ, J-HetQ, ili J-HetR, ili (11) C2-6 alkinil supstituiran sa CycQ, AriQ, HetQ, HetR, J-CycQ, J-AriQ, J-HetQ, ili J-HetR; svaki CycQ je neovisno C3-8 cikloalkil ili C5-8 cikloalkenil, pri čemu cikloalkil ili cikloalkenil je izborno supstituiran sa od 1 do 4 supstituenta, od kojih je svaki neovisno halogen, C1-6 alkil, OH, O-C1-6 alkil, C1-6 haloalkil ili O-C1-6 haloalkil; svaki AriQ je neovisno fenil ili naftil, gdje je fenil ili naftil izborno supstituiran sa od 1 do 5 supstituenata od kojih je svaki neovisno halogen, CN, NO2, C1-6 alkil, C1-6 haloalkil, OH, O-C1-6 alkil, O-C1-6 haloalkil, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SRA, S(O)RA, SO2RA, SO2N(RA)RB ili SO2N(RA)C(O)RB; svaki HetQ je neovisno heteroaril koji je izborno supstituiran sa od 1 do 4 supstituenta od kojih je svaki neovisno halogen, C1-6 alkil, C1-6 haloalkil, OH, O-C1-6 alkil, O-C1-6 haloalkil, N(RA)RB, C(O)N(RA)RB, C(O)RA, CO2RA, SO2RA, N(RA)C(O)N(RA)RB ili N(RA)CO2RB; svaki HetR je neovisno 4- do 7-člani, zasićeni ili nezasićeni, nearomatični heterociklični prsten koji sadrži najmanje jedan atom ugljika i od 1 do 4 heteroatoma neovisno izabrana od N, O i S, gdje je svaki S izborno oksidiran do S(O) ili S(O)2, i gdje je zasićeni ili nezasićeni heterociklični prsten izborno supstituiran sa od 1 do 4 supstituenta od kojih je svaki neovisno halogen, CN, C1-6 alkil, OH, okso, O-C1-6 alkil, C1-6 haloalkil, O-C1-6 haloalkil, C(O)N(RA)RB, C(O)RA, CO2RA, ili SO2RA; svaki J je neovisno: (i) O, (ii) S, (iii) S(O), (iv) S(O)2, (v) O-C1-6 alkilen, (vi) S-C1-6 alkilen, (vii) S(O)-C1-6 alkilen, (viii) S(O)2-C1-6 alkilen, (ix) N(RA), ili (x) N(RA)-C1-6 alkilen; svaki RA, RB, RC i RD su neovisno izabrani od H, C1-6 alkila i C3-6cikloalkila, pri čemu su navedeni C1-6 alkil i C3-6cikloalkil izborno supstituirani sa jednim ili više supstituenata do maksimalnog broja dozvoljenog valentnošću izabranog iz grupe koja se sastoji od: halogena, OH, CN, C1-4alkoksi, C3-6cikloalkila i fenila; ili alternativno svaki par RC i RD zajedno sa dušikom za koji su oba vezani formiraju 4- do 7-člani zasićeni ili mono-nezasićeni prsten koji izborno sadrži heteroatom pored N za koji su RC i RD vezani, pri čemu je dodatni heteroatom izabran od N, O i S; pri čemu je prsten izborno supstituiran sa 1 ili 2 supstituenta od kojih je svaki neovisno C1-6 alkil, C(O)RA, C(O)ORA, C(O)N(RA)RB ili S(O)2RA; i pri čemu je izborni S u prstenu izborno u obliku S(O) ili S(O)2 svaki aril je neovisno (i) fenil, (ii) 9- ili 10-člani biciklični, fuzionirani karbociklični sustav prstena u kojem je najmanje jedan prsten aromatičan, ili (iii) 11- do 14-člani tricikličan, fuzionirani karbocikličan sustav prstena u kojem je najmanje jedan prsten aromatičan; svaki heterociklil je neovisno (i) 4- do 8-člani, zasićeni ili nezasićeni monociklični prsten, (ii) 7- do 12-člani biciklični sustav prstena, ili (iii) 10- do 18-člani tricikličan sustav prstena, gdje je svaki prsten u (ii) ili (iii) neovisan od, fuzioniran sa ili premošćen sa drugim prstenom ili prstenovima i svaki prsten je zasićen ili nezasićen; gdje monocikličan prsten sadrži od 1 do 4 heteroatoma i ravnotežu atoma ugljika; bicikličan sustav prstena ili tricikličan sustav prstena sadrži od 1 do 8 heteroatoma i ravnotežu atoma ugljika, gdje jedan ili više od prstenova sadrže jedan ili više od heteroatoma; gdje su heteroatomi izabrani od N, O i S; i gdje su bilo koji ili više od heteroatoma dušika i sumpora izborno oksidirani, i bilo koji ili više od heteroatoma dušika je izborno kvaterniziran; svaki heteroaril je neovisno (i) 5- ili 6-člani heteroaromatični prsten koji sadrži od 1 do 4 heteroatoma neovisno izabrana od N, O i S, gdje je svaki N izborno u obliku oksida, ili (ii) 9- ili 10-člani heterobicikličan, fuzionirani sustav prstena koji sadrži od 1 do 6 heteroatoma neovisno izabrana od N, O i S, gdje bilo koji ili oba prstena sadrže jedan ili više od heteroatoma, najmanje jedan prsten je aromatičan, svaki N je izborno u obliku oksida i svaki S u prstenu koji nije aromatičan je izborno S(O) ili S(O)2.
2. Kombinacija prema patentnom zahtjevu 1, naznačena time što spoj formule (Ia) je izabrano od: [image] i [image] ili njegove farmaceutski prihvatljive soli.
3. Kombinacija prema patentnom zahtjevu 2, naznačena time što spoj formule (Ia) je: [image] ili njegova farmaceutski prihvatljiva sol.
4. Kombinacija prema patentnom zahtjevu 2, naznačena time što spoj formule (Ia) je: [image] ili njegova farmaceutski prihvatljiva sol.
5. Kombinacija prema patentnom zahtjevu 2, naznačena time što spoj formule (Ia) je: [image] ili njegova farmaceutski prihvatljiva sol.
6. Kombinacija prema patentnom zahtjevu 2, naznačena time što spoj formule (Ia) je: [image] ili njegova farmaceutski prihvatljiva sol.
7. Kombinacija prema patentnom zahtjevu 2, naznačena time što spoj formule (Ia) je: [image] ili njegova farmaceutski prihvatljiva sol.
8. Kombinacija prema bilo kojem od patentnih zahtjeva 1-7, naznačena time što jedno ili više sredstava protiv HIV-a je antivirusno sredstvo izabrano od inhibitora HIV proteaze, nukleozidnih inhibitora HIV reverzne transkriptaze, nenukleozidnih inhibitora HIV reverzne transkriptaze, inhibitora HIV integraze, inhibitora fuzije HIV-a i inhibitora ulaska HIV-a.
9. Kombinacija prema bilo kojem od patentnih zahtjeva 1-7, naznačena time što su jedan ili više sredstava protiv HIV-a izabrani od: abakavir, abakavir +lamivudin, abakavir + lamivudin + zidovudin, amprenavir, atazanavir, zidovudin, kapravirin darunavir, zalcitabin, didanozin, gastrorezistentno obložen didanozin, delavirdin, efavirenc, efavirenc + emtricitabin + tenofovir disoproksil fumarat, 4’-etinil-2-fluoro-2’-deoksiadenozin emtricitabin, emtricitabin + tenofovir disoproksil fumarat, emvirin, enfuvirtid, etravirin, fosamprenavir kalcij, indinavir, lamivudin, lamivudin + zidovudin, lopinavir lopinavir + ritonavir, maravirok, nelfinavir, nevirapin, PPL-100 raltegravir, ritonavir, sakvinavir, stavudin, tenofovir disoproksil fumarat, tenofovirheksadeciloksipropil tipranavir, abakavir sulfat, delavirdin mezilat, indinavir sulfat, atazanavir sulfat, nelfinavir mezilat i sakvinavir mezilat
10. Kombinacija prema patentnom zahtjevu 9, naznačena time što jedno ili više anti-HIV sredstava je 4'-etinil-2-fluoro-2'-deoksiadenozin.
11. Farmaceutska kompozicija koja sadrži kombinaciju prema bilo kojem od patentnih zahtjeva 1-10 i farmaceutski prihvatljiv nosač.
12. Kombinacija prema bilo kojem od patentnih zahtjeva 1-10, za uporabu u inhibiciji HIV reverzne transkriptaze kod subjekta.
13. Kombinacija prema bilo kojem od patentnih zahtjeva 1-10, za uporabu u profilaksi infekcije HIV-om ili profilaksi SIDA-e kod subjekta.
14. Kombinacija prema bilo kojem od patentnih zahtjeva 1-10, za uporabu u liječenju infekcije HIV-om, liječenju SIDA-e, ili odlaganju početka SIDA-e kod subjekta.
15. Kombinacija za uporabu prema bilo kojem od patentnih zahtjeva 12-14, naznačena time što subjekt je čovjek.
HRP20220502TT 2012-10-08 2013-10-07 Kombinacije koje sadrže derivate 5-fenoksi-3h-pirimidin-4-ona i njihova uporaba za profilaksu ili liječenje infekcije hiv-om HRP20220502T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012001358 2012-10-08
EP19210167.3A EP3656384B1 (en) 2012-10-08 2013-10-07 Combinations comprising 5-phenoxy-3h-pyrimidin-4-one derivatives and their use for the prophylaxis or treatment of infection by hiv

Publications (1)

Publication Number Publication Date
HRP20220502T1 true HRP20220502T1 (hr) 2022-05-27

Family

ID=49354986

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20220502TT HRP20220502T1 (hr) 2012-10-08 2013-10-07 Kombinacije koje sadrže derivate 5-fenoksi-3h-pirimidin-4-ona i njihova uporaba za profilaksu ili liječenje infekcije hiv-om
HRP20171819TT HRP20171819T1 (hr) 2012-10-08 2017-11-22 Derivati 5-fenoksi-3h-pirimidin-4-ona i njihova upotreba kao inhibitora hiv reverzne transkriptaze
HRP20200158TT HRP20200158T1 (hr) 2012-10-08 2020-01-30 Kombinacije koje sadrže derivate 5-fenoksi-3h-pirimidin-4-ona i njihova uporaba za profilaksu ili liječenje infekcije hiv-om

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20171819TT HRP20171819T1 (hr) 2012-10-08 2017-11-22 Derivati 5-fenoksi-3h-pirimidin-4-ona i njihova upotreba kao inhibitora hiv reverzne transkriptaze
HRP20200158TT HRP20200158T1 (hr) 2012-10-08 2020-01-30 Kombinacije koje sadrže derivate 5-fenoksi-3h-pirimidin-4-ona i njihova uporaba za profilaksu ili liječenje infekcije hiv-om

Country Status (47)

Country Link
US (3) US9469634B2 (hr)
EP (3) EP3295942B1 (hr)
JP (2) JP5877281B2 (hr)
KR (1) KR101696128B1 (hr)
CN (1) CN104822670B (hr)
AP (1) AP2015008355A0 (hr)
AR (1) AR092876A1 (hr)
AU (1) AU2013329552B8 (hr)
BR (1) BR112015007742B8 (hr)
CA (1) CA2887312C (hr)
CL (1) CL2015000880A1 (hr)
CO (1) CO7350655A2 (hr)
CR (1) CR20150183A (hr)
CY (3) CY1119655T1 (hr)
DK (3) DK3656384T3 (hr)
DO (1) DOP2015000082A (hr)
EA (1) EA033436B1 (hr)
EC (1) ECSP15018618A (hr)
ES (3) ES2770774T3 (hr)
GE (1) GEP20186838B (hr)
GT (1) GT201500088A (hr)
HK (2) HK1207369A1 (hr)
HR (3) HRP20220502T1 (hr)
HU (3) HUE037231T2 (hr)
IL (1) IL238090B (hr)
JO (1) JO3470B1 (hr)
LT (3) LT2903977T (hr)
MA (1) MA37959A2 (hr)
MD (1) MD4625C1 (hr)
ME (1) ME02918B (hr)
MX (1) MX355040B (hr)
MY (1) MY192716A (hr)
NI (1) NI201500048A (hr)
NO (1) NO2903977T3 (hr)
NZ (1) NZ706729A (hr)
PE (1) PE20151787A1 (hr)
PH (1) PH12015500764B1 (hr)
PL (3) PL3656384T3 (hr)
PT (3) PT3656384T (hr)
RS (3) RS63112B1 (hr)
SG (1) SG11201502620UA (hr)
SI (3) SI2903977T1 (hr)
TN (1) TN2015000106A1 (hr)
TW (2) TWI598343B (hr)
UA (1) UA114006C2 (hr)
WO (1) WO2014058747A1 (hr)
ZA (1) ZA201503143B (hr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
UY35735A (es) 2013-09-16 2015-04-30 Bayer Pharma AG Trifluorometilpirimidinonas disustituidas y su uso
US10004740B2 (en) * 2014-04-01 2018-06-26 Merck Sharp & Dohme Corp. Prodrugs of HIV reverse transcriptase inhibitors
ES2901114T3 (es) 2014-08-29 2022-03-21 Tes Pharma S R L Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa
FR3027901B1 (fr) * 2014-10-31 2018-03-16 Universite De Reims Champagne Ardenne Nouveaux procedes appartenant a la famille des pyridazinones.
US10350165B2 (en) * 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
CN108513575A (zh) 2015-10-23 2018-09-07 哈佛大学的校长及成员们 核碱基编辑器及其用途
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
SG11201908658TA (en) 2017-03-23 2019-10-30 Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
WO2019055966A2 (en) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. PYRIDAZINONES AND METHODS OF USE
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
AU2019217875A1 (en) 2018-02-06 2020-08-20 Icahn School Of Medicine At Mount Sinai Repeat RNA as biomarkers of tumor immune response
PT3788040T (pt) 2018-04-30 2023-07-12 Ribon Therapeutics Inc Piridazinonas como inibidores de parp7
BR112021004926A2 (pt) 2018-09-18 2021-06-01 Goldfinch Bio, Inc. piridazinonas e métodos de uso das mesmas
EP3898595B1 (en) * 2018-12-18 2024-05-01 Merck Sharp & Dohme LLC Pyrimidone derivatives as selective cytotoxic agents against hiv infected cells
DE112020001342T5 (de) 2019-03-19 2022-01-13 President and Fellows of Harvard College Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
MX2021014247A (es) * 2019-05-22 2022-01-06 Merck Sharp & Dohme Llc Derivados piridinona como agentes citotoxicos selectivos contra celulas infectadas con virus de inmunodeficiencia humana (vih).
AU2020357178A1 (en) * 2019-10-04 2022-05-12 Goldfinch Bio, Inc. Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
AU2020375821A1 (en) 2019-10-30 2022-06-02 Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibitors
TW202133858A (zh) 2019-11-28 2021-09-16 日商鹽野義製藥股份有限公司 以組合整合酶阻礙劑及抗ｈｉｖ藥為特徵之ｈｉｖ感染症的預防及治療用醫藥
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
EP4146804A1 (en) 2020-05-08 2023-03-15 The Broad Institute Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
JP2023543803A (ja) 2020-09-24 2023-10-18 ザ ブロード インスティテュート，インコーポレーテッド プライム編集ガイドｒｎａ、その組成物、及びその使用方法
EP4274894A2 (en) 2021-01-11 2023-11-15 The Broad Institute, Inc. Prime editor variants, constructs, and methods for enhancing prime editing efficiency and precision
AU2022301461A1 (en) * 2021-07-01 2024-02-15 Janssen Pharmaceutica Nv 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides
CA3227004A1 (en) 2021-08-06 2023-02-09 The Broad Institute, Inc. Improved prime editors and methods of use
WO2023076898A1 (en) 2021-10-25 2023-05-04 The Broad Institute, Inc. Methods and compositions for editing a genome with prime editing and a recombinase
WO2023102538A1 (en) 2021-12-03 2023-06-08 The Broad Institute, Inc. Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
WO2023205687A1 (en) 2022-04-20 2023-10-26 The Broad Institute, Inc. Improved prime editing methods and compositions
WO2023240137A1 (en) 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
WO2024077267A1 (en) 2022-10-07 2024-04-11 The Broad Institute, Inc. Prime editing methods and compositions for treating triplet repeat disorders
WO2024108092A1 (en) 2022-11-17 2024-05-23 The Broad Institute, Inc. Prime editor delivery by aav

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
BR9909976A (pt) 1998-04-27 2000-12-26 Centre Nat Rech Scient Composto, processo para a obtenção de compostos, derivado litiado, composições farmacêuticas, e, processos de tratamento de doenças relacionadas com hiv e de tratamento de infecção de hiv
IT1305313B1 (it) 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
HUP0302173A2 (hu) 2000-09-15 2003-09-29 Vertex Pharmaceuticals Incorporated Protein kináz inhibitorokként alkalmazható pirazolvegyületek
KR20110132482A (ko) 2003-02-07 2011-12-07 얀센 파마슈티카 엔.브이. Ｈｉｖ 감염 예방용 피리미딘 유도체
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
AU2004224191A1 (en) * 2003-03-24 2004-10-07 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
AU2005206511A1 (en) 2004-01-12 2005-08-04 Gilead Sciences, Inc. Pyrimidyl phosphonate antiviral compounds and methods of use
CN1934092A (zh) 2004-03-23 2007-03-21 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
SG152263A1 (en) 2004-04-23 2009-05-29 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
JP2008525419A (ja) 2004-12-22 2008-07-17 ファイザー・リミテッド Ｈｉｖ−１逆転写酵素の非ヌクレオシド阻害剤
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
BRPI0617482A2 (pt) 2005-10-19 2011-07-26 Hoffmann La Roche compostos inibidores de transcriptase reversa nço-nucleosÍdeos de n-fenil fenilacetamida, composiÇço farmacÊutica contendo os referidos compostos bem como seus usos
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 ｎｎｒｔ 저해제
US7803940B2 (en) 2006-11-24 2010-09-28 Takeda Pharmaceutical Company Limited Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases
CA2670404A1 (en) 2006-11-24 2008-05-29 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
WO2009067166A2 (en) * 2007-11-20 2009-05-28 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
AU2008346833B2 (en) * 2008-01-08 2014-07-17 Merck Sharp & Dohme Corp. Process for preparing N-substituted hydroxypyrimidinone carboxamides
DK2924034T3 (en) * 2010-03-30 2017-02-06 Merck Canada Inc PHARMACEUTICAL COMPOSITION CONTAINING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR
WO2011126969A1 (en) 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Prodrugs of an hiv reverse transcriptase inhibitor
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
US10004740B2 (en) 2014-04-01 2018-06-26 Merck Sharp & Dohme Corp. Prodrugs of HIV reverse transcriptase inhibitors

Also Published As

Publication number Publication date
US20170349585A1 (en) 2017-12-07
SI3295942T1 (sl) 2020-03-31
CA2887312A1 (en) 2014-04-17
CA2887312C (en) 2017-02-28
CL2015000880A1 (es) 2015-08-28
IL238090B (en) 2019-02-28
MX2015004448A (es) 2016-02-17
MX355040B (es) 2018-03-28
CN104822670B (zh) 2018-01-12
EP3656384A1 (en) 2020-05-27
HK1207369A1 (en) 2016-01-29
CO7350655A2 (es) 2015-08-10
CY1125202T1 (el) 2024-02-16
PT3656384T (pt) 2022-03-22
JO3470B1 (ar) 2020-07-05
RS63112B1 (sr) 2022-05-31
RS56543B1 (sr) 2018-02-28
AP2015008355A0 (en) 2015-04-30
DOP2015000082A (es) 2015-08-16
US9469634B2 (en) 2016-10-18
CY1119655T1 (el) 2018-04-04
TW201420576A (zh) 2014-06-01
HUE048670T2 (hu) 2020-08-28
ES2770774T3 (es) 2020-07-03
TN2015000106A1 (en) 2016-06-29
PL3656384T3 (pl) 2022-04-04
SI3656384T1 (sl) 2022-05-31
JP6097422B2 (ja) 2017-03-15
BR112015007742A2 (pt) 2017-08-08
ES2909190T3 (es) 2022-05-05
TWI538907B (zh) 2016-06-21
BR112015007742B8 (pt) 2021-03-23
WO2014058747A1 (en) 2014-04-17
ME02918B (me) 2018-10-20
ZA201503143B (en) 2016-06-29
EP3295942A1 (en) 2018-03-21
CR20150183A (es) 2015-08-10
LT3656384T (lt) 2022-05-10
ECSP15018618A (es) 2019-06-30
RS59863B1 (sr) 2020-03-31
MD4625B1 (ro) 2019-04-30
EA201590674A1 (ru) 2016-02-29
NI201500048A (es) 2016-06-29
NO2903977T3 (hr) 2018-02-17
DK2903977T3 (en) 2017-12-04
AU2013329552C1 (en) 2016-12-22
JP2016128470A (ja) 2016-07-14
PL2903977T3 (pl) 2018-01-31
TWI598343B (zh) 2017-09-11
CN104822670A (zh) 2015-08-05
KR101696128B1 (ko) 2017-01-13
US9718819B2 (en) 2017-08-01
HUE037231T2 (hu) 2018-08-28
PT2903977T (pt) 2017-11-14
LT2903977T (lt) 2017-12-11
US20160145255A1 (en) 2016-05-26
AU2013329552B2 (en) 2016-09-15
HRP20200158T1 (hr) 2020-08-07
GEP20186838B (en) 2018-04-10
AU2013329552A1 (en) 2015-04-16
AU2013329552B8 (en) 2017-01-12
BR112015007742B1 (pt) 2021-01-19
PT3295942T (pt) 2020-02-18
AR092876A1 (es) 2015-05-06
EA033436B1 (ru) 2019-10-31
MA37959A2 (fr) 2017-12-29
US10189831B2 (en) 2019-01-29
US20140100231A1 (en) 2014-04-10
UA114006C2 (xx) 2017-04-10
LT3295942T (lt) 2020-02-10
SI2903977T1 (sl) 2017-12-29
NZ706729A (en) 2018-09-28
EP2903977B1 (en) 2017-09-20
MD4625C1 (ro) 2019-11-30
TW201623256A (zh) 2016-07-01
DK3656384T3 (da) 2022-04-19
DK3295942T3 (da) 2020-02-10
HK1252786A1 (zh) 2019-05-31
JP2015533123A (ja) 2015-11-19
HUE058903T2 (hu) 2022-09-28
EP3295942B1 (en) 2019-11-20
PH12015500764A1 (en) 2015-07-27
MY192716A (en) 2022-09-05
PH12015500764B1 (en) 2015-07-27
MD20150047A2 (ro) 2015-08-31
CY1122585T1 (el) 2021-01-27
JP5877281B2 (ja) 2016-03-02
EP2903977A1 (en) 2015-08-12
GT201500088A (es) 2017-09-28
EP3656384B1 (en) 2022-02-23
PE20151787A1 (es) 2015-12-03
HRP20171819T1 (hr) 2017-12-29
PL3295942T3 (pl) 2020-05-18
ES2645638T3 (es) 2017-12-07
SG11201502620UA (en) 2015-05-28
KR20150065186A (ko) 2015-06-12

Similar Documents

Publication Publication Date Title
HRP20220502T1 (hr) Kombinacije koje sadrže derivate 5-fenoksi-3h-pirimidin-4-ona i njihova uporaba za profilaksu ili liječenje infekcije hiv-om
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
HRP20150427T1 (hr) Ne-nukleozidni inhibitori reverzne transkriptaze
HRP20210038T1 (hr) Pirolopirimidini za uporabu u infekciji virusom gripe
JP2019509276A5 (hr)
JP2019527718A5 (hr)
HRP20211622T1 (hr) 4'-supstituirani nukleozidni-derivati kao inhibitori hiv reverzne transkriptaze
JOP20190090B1 (ar) مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان
HRP20160647T1 (hr) Novi heterociklički derivati i njihova uporaba u liječenju neuroloških poremećaja
WO2015132799A3 (en) Heterocyclic compounds
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
HRP20211278T1 (hr) Supstituirani derivati indolina kao inhibitori replikacije denga virusa
EA201890888A1 (ru) Новые спиро[3h-индол-3,2'-пирролидин]-2(1h)-оновые соединения и производные в качестве ингибиторов mdm2-p53
HRP20201780T1 (hr) Prolijekovi inhibitora hiv reverzne transkriptaze
HRP20201949T1 (hr) 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
EA201891463A1 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИН-4-ИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ (JAK)
EA201650029A1 (ru) Пиразолопиридины и пиразолопиримидины
HRP20191826T4 (hr) Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta
HRP20202051T1 (hr) Aril supstituirani pirimidini za uporabu kod infekcije virusom influence
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
WO2018042362A9 (en) Muscarinic m1 receptor positive allosteric modulators
HRP20201211T1 (hr) Derivat dihidropiridazin-3,5-diona
HRP20201522T1 (hr) Heteroaromatski nmda receptor modulatori i njihove uporabe